Amylyx Pharmaceuticals (NASDAQ:AMLX) Given New $33.00 Price Target at Citigroup

Amylyx Pharmaceuticals (NASDAQ:AMLX – Get Rating) had its price target raised by equities researchers at Citigroup from $32.00 to $33.00 in a report issued on Tuesday, Stock Target Advisor reports. The firm presently has a “buy” rating on the stock. Citigroup’s price target suggests a potential upside of 145.17% from the stock’s current price. Amylyx […]

Related Keywords

United States ,Canada , ,Amylyx Pharmaceuticals ,Amylyx Pharmaceuticals Inc ,Analyst Recommendations For Amylyx Pharmaceuticals ,Amylyx Pharmaceuticals Company Profile Get Rating ,Citigroup ,Get Rating ,Stock Target Advisor ,Pharmaceuticals Company Profile ,Target Advisor ,Nasdaq Amlx ,Amlx ,Medical ,Boost Price Target ,Citigroup Inc ,